Alexium International Group Ltd (ASX: AJX) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Alexium International Group Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $46.83 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 640.64 million
Earnings per share -0.002
Dividend per share N/A
Year To Date Return 27.59%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Alexium International Group Ltd (ASX: AJX)
Latest News

AJX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Alexium International Group Ltd

Alexium International Group Ltd is engaged in the development of specialty chemicals. Its only operating segment being the development and licensing of its proprietary flame retardant (FR) and phase change material (PCM) chemistries, reactive surface treatment (RST) technologies, and selling its specialised chemistry to customers. Geographically, it derives a majority of revenue from the United States and also has a presence in Australia and Cyprus. The company products include Alexicool and Alexiflam NF.

AJX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
01 Dec 2021 $0.07 $0.00 0.00% 383,954 $0.08 $0.08 $0.07
30 Nov 2021 $0.08 $0.00 0.00% 139,127 $0.08 $0.08 $0.08
29 Nov 2021 $0.08 $0.00 0.00% 910,111 $0.08 $0.08 $0.08
26 Nov 2021 $0.08 $-0.01 -11.90% 1,319,542 $0.08 $0.08 $0.08
25 Nov 2021 $0.08 $0.00 0.00% 344,749 $0.08 $0.08 $0.08
24 Nov 2021 $0.08 $0.00 0.00% 1,066,185 $0.09 $0.09 $0.08
23 Nov 2021 $0.09 $0.00 0.00% 297,889 $0.09 $0.09 $0.09
22 Nov 2021 $0.09 $0.00 0.00% 720,728 $0.09 $0.09 $0.09
19 Nov 2021 $0.09 $0.00 0.00% 528,179 $0.09 $0.09 $0.09
18 Nov 2021 $0.09 $0.00 0.00% 290,102 $0.09 $0.09 $0.09
17 Nov 2021 $0.09 $0.00 0.00% 1,519,444 $0.09 $0.09 $0.09
16 Nov 2021 $0.09 $0.00 0.00% 140,281 $0.09 $0.09 $0.09
15 Nov 2021 $0.09 $0.00 0.00% 171,663 $0.09 $0.09 $0.09
12 Nov 2021 $0.09 $0.00 0.00% 522,779 $0.09 $0.09 $0.09
11 Nov 2021 $0.09 $0.00 0.00% 693,184 $0.09 $0.09 $0.09
10 Nov 2021 $0.09 $0.00 0.00% 549,427 $0.09 $0.09 $0.09
09 Nov 2021 $0.09 $0.00 0.00% 2,442,081 $0.09 $0.10 $0.09
08 Nov 2021 $0.09 $0.00 0.00% 491,011 $0.09 $0.09 $0.09
05 Nov 2021 $0.09 $0.00 0.00% 725,407 $0.09 $0.09 $0.09
04 Nov 2021 $0.09 $0.00 0.00% 417,319 $0.09 $0.09 $0.09
03 Nov 2021 $0.09 $0.00 0.00% 188,827 $0.09 $0.09 $0.09
02 Nov 2021 $0.09 $0.00 0.00% 229,837 $0.09 $0.09 $0.09

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
25 Oct 2021 Brigadier Gen. Stephen Cheney Issued 175 $13,348
Director remuneration.
25 Oct 2021 Robert (Bob) Brookins Issued 471 $41,466
Issue of securities. 1,081,974 - performance rights
25 Oct 2021 Rosheen Garnon Issued 270 $20,536
Director remuneration.
13 May 2021 Simon Moore Buy 4 $213,278
On-market trade.
12 May 2021 Simon Moore Buy 363 $16,721
On-market trade.
21 Apr 2021 Brigadier Gen. Stephen Cheney Issued 235 $9,729
Director remuneration.
21 Apr 2021 Rosheen Garnon Issued 362 $14,968
Director remuneration.
22 Dec 2020 Rosheen Garnon Issued 317 $43,567
Director remuneration.
22 Dec 2020 Brigadier Gen. Stephen Cheney Issued 206 $28,318
Director remuneration.
08 Dec 2020 Robert (Bob) Brookins Buy 980 $62,745
08 Dec 2020 Robert (Bob) Brookins Exercise 471 $30,157
Conversion of securities. 2,086,407 - performance rights
08 Dec 2020 Robert (Bob) Brookins Cancelled 539 $34,496
Cancellation of securities. As per announcement on 11/12/2020.
08 Dec 2020 Robert (Bob) Brookins Issued 418 $26,793
Issue of securities. 2,557,620 - performance rights
08 Dec 2020 Robert (Bob) Brookins Expiry 1 $94,442
As advised by the company. 610,763 - performance rights
lapsed performance rights
08 Dec 2020 Robert (Bob) Brookins Buy 471 $30,157
Conversion of securities.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Simon Colinton Moore Non-Executive Director Feb 2020
Mr Moore is the Senior Partner of investment firm, Colinton Capital Partners. Prior to establishing Colinton Capital Partners in 2017, Mr Moore was a Global Partner of The Carlyle Group having established their operation in Australia in 2005. In his time at The Carlyle Group, he oversaw the Firm's investments in and served on the Boards of Directors of Coates Hire, Healthscope and Qube
Brigadier Gen. Stephen Cheney Non-Executive Director Apr 2015
Mr Cheney is the former Inspector Mr of the Marine Corps and Commanding Mr of Parris Island Marine Base. He is also the former Deputy Executive Secretary to US Defence Secretary Dick Cheney under President George H.W. Bush. Mr Cheney sat on Secretary of State John Kerry's Foreign Affairs Policy Board and is the President of the Washington D.C. based 501(C)3 policy group The American Security Project as well as President of their 501(C)(4) company The American Security Action Fund.
Dr Robert (Bob) Brookins Chief Executive OfficerManaging Director May 2018
Dr Brookins has more than 15 years of experience in organic synthesis and materials chemistry. He received his PhD from the University of Florida in the areas of synthesis and characterisation of conjugated polyelectrolytes and polymers with an emphasis on developing new polymerisation methods. Upon completion of his PhD, he worked at the US Air Force Research Laboratory at Tyndall AFB, FL where he developed decontamination methods for chemical and biological threats and developed novel synthetic routes for reactive and functional surfaces. In 2010, Dr Brookins joined Alexium where he and his team pioneered new classes of flame retardants for key textile markets. Additionally, his research focuses on phase change materials, particularly novel application methods and analytical tools. Dr Brookins has been instrumental in the research and development of the Company's innovative technologies. Dr Brookins led the development and commercialisation of Alexium's phase change material (PCM) platform technologies and the Alexicool product line, which is the foundation of the Company's success in the bedding and top-of-bed markets. Dr Brookins has, during his 8 years with the Company, been involved in multiple facets of the business, including working with customers on product design and marketing, analysing markets to assess opportunities, and planning for logistics and supply-chain management. In addition, Dr Brookins co-invented Alexium's flame retardant (FR) technologies for military uniforms and formaldehyde-free, flame retardant products for cotton-based materials. Dr Brookins has been immersed in the operations and strategy of the business and has gained significant experience working within the senior leadership team of the Company
Mrs Rosheen Garnon Non-Executive DirectorNon-Executive Chairman Sep 2018
Mrs Garnon has had a distinguished career in the accounting profession as a chartered accountant and taxation advisor. She was a senior partner with KPMG and held senior executive leadership roles with the firm in Australia and at a global level. Mrs Garnon was a member of the KPMG Australian Executive Leadership Team for six years as the National Managing Partner for the Taxation Division. She has experience of working with Boards and C Suite executives. Mrs Garnon is a Non-Executive Director of Australian Rail Track Corporation, a Non-Executive Director of Resolution Life Australia, and a NonExecutive Director of Venues NSW. She is Chair of the Board of Taxation, an independent advisory board, that advises the Federal Treasurer and the Assistant Treasurer on Australia's taxation system. Her not for profit and volunteer roles include a Non-Executive Director of The Smith Family; Deputy Chair of the Australia Council for the Arts; a Non-Executive Director of Creative Partnerships Australia; Member of the Finance Committee, The University of Sydney, and a Non-Executive Director of Women Corporate Directors.
Dr Paul Henry Stenson Non-Executive Director Jun 2020
Dr Stenson has a career with the research, development, manufacture, and commercialisation of new materials in the fields of coatings, adhesives, nonwovens, and pharmaceuticals. Dr Stenson has been President and CEO of StanChem Inc. since January 2018. StanChem Inc. comprises two companies - StanChem Polymers which is a manufacturer of water-based polymers for the coatings and adhesives industries, and Albi Protective Coatings which focuses on the specialty sector of fire protective intumescent paints. Prior to joining StanChem in 2017, Dr Stenson worked as a global technology director at Axalta Coating Systems. Between 2011 and 2016, Dr Stenson was the executive vice president of technology and product development at Ahlstrom for nonwoven and specialty high performance paper products. Prior to joining Ahlstrom, Dr Stenson was the vice president of technology for industrial and packaging coatings at Valspar based in Minneapolis and Zurich, Switzerland from 1993 until 2011. Dr Stenson is also the chairman of TopChem Pharmaceuticals (Ireland) which is a manufacturer of active pharmaceutical ingredients
Mr Carl Bradley Dennis Non-Executive Director Sep 2021
Mr Dennis is an operational management executive with over 25 years' experience in Consumer and Pharmaceutical Goods. As a former CEO and commercial director, Mr Dennis has gained experience in new product development, sales and marketing, international brand management and operational execution. Mr Dennis was the CEO and co-owner of Vital Merchandising Services for 11 years which was acquired by Imperial Logistics Limited in 2007, and he went on to hold both operational and business development roles with Imperial Logistics. Throughout his career, his clients have included Blue Chip FMCG organizations. Over the past five years Mr Dennis has focused in creating new markets for international Australian consumer brands across Asia, Middle East and Africa.
Mr Mark Andrew Licciardo Company Secretary Mar 2020
Mr Allen Reihman Chief Commercial Officer
Mr Jason Lewis Chief Financial Officer
Mark Andrew Licciardo Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Colinton Capital Partners Pty Ltd <Colinton Cp Fund 1 (A) A/C> 76,145,234 11.89%
Sandhurst Trustees Ltd <Wentworth Williamson A/C> 55,188,743 8.62%
Dr Stuart Lloyd Phillips & Mrs Fiona Jane Phillips <Sl & Fj Phillips Pens F A/C 38,225,000 5.97%
BNP Paribas Nominees Pty Ltd Acf Clearstream 33,780,770 5.28%
Naam Group Pty Ltd <Naam Investment A/C> 18,874,256 2.95%
J P Morgan Nominees Australia Pty Limited 10,254,901 1.60%
HSBC Custody Nominees (Australia) Limited <Euroclear Bank SA Nv A/C> 9,947,055 1.55%
Ddh Graham Limited <The Lugarno Fund A/C> 9,200,000 1.44%
Dr Stuart Lloyd Phillips & Mrs Fiona Jane Phillips <Sl & Fj Phillips S/F A/C> 8,645,000 1.35%
Mr Herman Brookins 8,333,333 1.30%
Ducky'S Lifeline Pty Ltd <The R Edwards Super A/C> 8,300,552 1.30%
HSBC Custody Nominees (Australia) Limited 5,518,613 0.86%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <DRP A/C> 5,487,993 0.86%
Mr Martin Keith Thomas & Mrs Helen Patricia Thomas 5,431,500 0.85%
Lomand Services Limited 5,281,500 0.82%
Cannow Pty Ltd <C & T Family S/Fund A/C> 4,400,000 0.69%
BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 4,260,062 0.67%
David Rivett Pty Limited <Super Fund A/C> 4,000,000 0.62%
Citicorp Nominees Pty Limited 3,751,175 0.59%
Ms Frances Elizabeth Phillips & Mr Stuart Lloyd Phillips <Francesphillipssuperfnd A/C> 3,568,966 0.56%